Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Why Eli Lilly Stock Topped the Market Today
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Investor's Business Daily on MSN23h
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.